Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

As Adam Fein of Drug Channels Institute puts it, these forces are finally puncturing the “ gross-to-net bubble ”—the vast gap ...

Citing topline data from its Phase 3 TRIUMPH-4, the Indiana-based drugmaker said that retatrutide, a GIP, GLP-1, and glucagon triple hormone receptor agonist, at the two highest doses led to ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...